Cyproheptadine: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "5 mg" to "5mg") |
(Add peer-reviewed reference) |
||
| (6 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
==Uses== | ==Uses== | ||
*Treatment of serotonin syndrome | *Treatment of serotonin syndrome<ref>Graudins A, et al. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med. 1998;16(4):615-619. PMID 9696181</ref> | ||
==Administration== | ==Administration== | ||
*Dosage Forms: | *Dosage Forms: 4mg tab, 2mg/5ml solution | ||
*Routes of Administration: oral | *Routes of Administration: oral | ||
*Common Trade Names: Periactin or Peritol | *Common Trade Names: Periactin or Peritol | ||
| Line 12: | Line 12: | ||
*Children younger than two years can be given approximately 0.06mg/kg per dose every six hours, if needed (not to exceed 0.25mg/kg/day). | *Children younger than two years can be given approximately 0.06mg/kg per dose every six hours, if needed (not to exceed 0.25mg/kg/day). | ||
*Children two to six years can be given 2mg every six hours, if needed (not to exceed 12mg/day). | *Children two to six years can be given 2mg every six hours, if needed (not to exceed 12mg/day). | ||
*Children 7 to 14 years can be given | *Children 7 to 14 years can be given 4mg every six hours, if needed (not to exceed 16mg/day). | ||
==Special Populations== | ==Special Populations== | ||
| Line 32: | Line 32: | ||
===Common=== | ===Common=== | ||
*Sedation | *Sedation | ||
==Pharmacology== | |||
* Half-life: 1-4 hours | |||
* Metabolism: Liver | |||
* Excretion: Urine | |||
==Mechanism of Action== | ==Mechanism of Action== | ||
| Line 39: | Line 44: | ||
==Comments== | ==Comments== | ||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Cyproheptadine]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
==See Also== | ==See Also== | ||
| Line 45: | Line 67: | ||
*1. Boyer EW. Serotonin syndrome. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on January 11, 2016.) | *1. Boyer EW. Serotonin syndrome. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on January 11, 2016.) | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] [[Category:Toxicology]] | ||
Latest revision as of 10:18, 22 March 2026
Uses
- Treatment of serotonin syndrome[1]
Administration
- Dosage Forms: 4mg tab, 2mg/5ml solution
- Routes of Administration: oral
- Common Trade Names: Periactin or Peritol
Adult Dosing
- initial dose of 12mg is recommended, followed by 2mg every two hours until clinical response is seen
Pediatric Dosing
- Children younger than two years can be given approximately 0.06mg/kg per dose every six hours, if needed (not to exceed 0.25mg/kg/day).
- Children two to six years can be given 2mg every six hours, if needed (not to exceed 12mg/day).
- Children 7 to 14 years can be given 4mg every six hours, if needed (not to exceed 16mg/day).
Special Populations
Renal Dosing
- No recommendations
Hepatic Dosing
- No recommendations
Contraindications
- Allergy to class/drug
- Treatment in newborns or nursing mothers
Adverse Reactions
Serious
- Hypotension
Common
- Sedation
Pharmacology
- Half-life: 1-4 hours
- Metabolism: Liver
- Excretion: Urine
Mechanism of Action
- Histamine-1 receptor antagonist
- 5-HT1A and 5-HT2A (seritonin) antagonistic properties
- Weak anticholinergic activity
Comments
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
See Also
References
- 1. Boyer EW. Serotonin syndrome. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on January 11, 2016.)
- ↑ Graudins A, et al. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med. 1998;16(4):615-619. PMID 9696181